• Underlying revenue growth of 12.0% to $12.3 billion
• Underlying EBITDA of $585 million, up 7.5% on FY24
• Strong Underlying free cash flow of $302 million, with a cash realisation of 109%

EBOS Group Limited today reports its full year results to 30 June 2025 (FY25). The results highlight EBOS' continued track record of solid organic growth, operational excellence and strategic execution. EBOS' operating results included Underlying revenue growth of 12.0% to $12.3 billion, GOR of $1.6 billion and Underlying EBITDA of $585 million, up 7.5% on FY24. The Group also generated strong Underlying free cash flow of $302 million, with a cash realisation of 109%. The Healthcare segment delivered impressive results, achieving growth through new customer wins in Pharmacy wholesale and Contract Logistics, driving double-digit revenue growth. Within Animal Care, the branded business continued its growth momentum supported by new product development launches. EBOS has delivered against its near-term strategic priorities, delivering profitable growth with a strong focus on maintaining EBITDA margins. The Group remains confident in the growth across both the Healthcare and Animal Care segments, and the portfolio is uniquely placed through its leading brands and positions to capture the benefit arising from these supportive long-term industry trends.

In FY26, the Group is targeting Underlying EBITDA of $615 - 635 million, reflecting ~7% midpoint growth, with positive contributions from both the Healthcare and Animal Care segments. In FY26, we expect capital expenditure of approximately $130 - 140 million, marking the successful completion of our major distribution centre renewal program.

Our portfolio is well positioned for long-term growth with continued positive healthcare and animal care industry trends supporting the resilience of our businesses. Near-term macro pressures include a competitive wholesale pharmacy environment, soft hospital capital spend and subdued consumer sentiment impacting discretionary pet categories.